Guardant Health (GH) Stock Analysis & Winston Score

Guardant Health is a medical company that makes blood tests to detect and monitor cancer. Instead of a traditional tissue biopsy — which requires surgery — Guardant's tests analyze fragments of tumor DNA floating in a patient's blood, a technique called "liquid biopsy." Its main products include the Guardant360 test for guiding cancer treatment decisions and Shield, a colorectal cancer screening test approved by the FDA in 2024 for average-risk adults. The company earns revenue by selling these tests to oncologists, hospitals, and health systems, and is working to expand insurance coverage to reach more patients. Guardant operates primarily in the United States, with some international presence, and generated roughly $700 million in annual revenue in recent periods. Its moat comes from proprietary technology, large clinical datasets, and regulatory approvals that are difficult for competitors to replicate quickly. The biggest challenge ahead is convincing insurers to broadly reimburse Shield, since widespread coverage is essential for the test to become commercially viable at scale.